Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha.
BACKGROUND:Malaria caused by Plasmodium falciparum is one of the major threats to human health globally. Despite huge efforts in malaria control and eradication, highly effective vaccines are urgently needed, including vaccines that can block malaria transmission. Chimeric virus-like particles (VLP)...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0221394 |
id |
doaj-16530a1b9a194067a2d02bbdb2c34057 |
---|---|
record_format |
Article |
spelling |
doaj-16530a1b9a194067a2d02bbdb2c340572021-03-03T20:31:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01149e022139410.1371/journal.pone.0221394Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha.David WetzelJo-Anne ChanManfred SuckowAndreas BarbianMichael WenigerVolker JenzelewskiLinda ReilingJack S RichardsDavid A AndersonBetty KouskousisCatherine PalmerEric HanssenGerhard SchembeckerJuliane MerzJames G BeesonMichael PiontekBACKGROUND:Malaria caused by Plasmodium falciparum is one of the major threats to human health globally. Despite huge efforts in malaria control and eradication, highly effective vaccines are urgently needed, including vaccines that can block malaria transmission. Chimeric virus-like particles (VLP) have emerged as a promising strategy to develop new malaria vaccine candidates. METHODS:We developed yeast cell lines and processes for the expression of malaria transmission-blocking vaccine candidates Pfs25 and Pfs230 as VLP and VLP were analyzed for purity, size, protein incorporation rate and expression of malaria antigens. RESULTS:In this study, a novel platform for the display of Plasmodium falciparum antigens on chimeric VLP is presented. Leading transmission-blocking vaccine candidates Pfs25 and Pfs230 were genetically fused to the small surface protein (dS) of the duck hepatitis B virus (DHBV). The resulting fusion proteins were co-expressed in recombinant Hansenula polymorpha (syn. Pichia angusta, Ogataea polymorpha) strains along with the wild-type dS as the VLP scaffold protein. Through this strategy, chimeric VLP containing Pfs25 or the Pfs230-derived fragments Pfs230c or Pfs230D1M were purified. Up to 100 mg chimeric VLP were isolated from 100 g dry cell weight with a maximum protein purity of 90% on the protein level. Expression of the Pfs230D1M construct was more efficient than Pfs230c and enabled VLP with higher purity. VLP showed reactivity with transmission-blocking antibodies and supported the surface display of the malaria antigens on the native VLP. CONCLUSION:The incorporation of leading Plasmodium falciparum transmission-blocking antigens into the dS-based VLP scaffold is a promising novel strategy for their display on nano-scaled particles. Competitive processes for efficient production and purification were established in this study.https://doi.org/10.1371/journal.pone.0221394 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
David Wetzel Jo-Anne Chan Manfred Suckow Andreas Barbian Michael Weniger Volker Jenzelewski Linda Reiling Jack S Richards David A Anderson Betty Kouskousis Catherine Palmer Eric Hanssen Gerhard Schembecker Juliane Merz James G Beeson Michael Piontek |
spellingShingle |
David Wetzel Jo-Anne Chan Manfred Suckow Andreas Barbian Michael Weniger Volker Jenzelewski Linda Reiling Jack S Richards David A Anderson Betty Kouskousis Catherine Palmer Eric Hanssen Gerhard Schembecker Juliane Merz James G Beeson Michael Piontek Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha. PLoS ONE |
author_facet |
David Wetzel Jo-Anne Chan Manfred Suckow Andreas Barbian Michael Weniger Volker Jenzelewski Linda Reiling Jack S Richards David A Anderson Betty Kouskousis Catherine Palmer Eric Hanssen Gerhard Schembecker Juliane Merz James G Beeson Michael Piontek |
author_sort |
David Wetzel |
title |
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha. |
title_short |
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha. |
title_full |
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha. |
title_fullStr |
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha. |
title_full_unstemmed |
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha. |
title_sort |
display of malaria transmission-blocking antigens on chimeric duck hepatitis b virus-derived virus-like particles produced in hansenula polymorpha. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
BACKGROUND:Malaria caused by Plasmodium falciparum is one of the major threats to human health globally. Despite huge efforts in malaria control and eradication, highly effective vaccines are urgently needed, including vaccines that can block malaria transmission. Chimeric virus-like particles (VLP) have emerged as a promising strategy to develop new malaria vaccine candidates. METHODS:We developed yeast cell lines and processes for the expression of malaria transmission-blocking vaccine candidates Pfs25 and Pfs230 as VLP and VLP were analyzed for purity, size, protein incorporation rate and expression of malaria antigens. RESULTS:In this study, a novel platform for the display of Plasmodium falciparum antigens on chimeric VLP is presented. Leading transmission-blocking vaccine candidates Pfs25 and Pfs230 were genetically fused to the small surface protein (dS) of the duck hepatitis B virus (DHBV). The resulting fusion proteins were co-expressed in recombinant Hansenula polymorpha (syn. Pichia angusta, Ogataea polymorpha) strains along with the wild-type dS as the VLP scaffold protein. Through this strategy, chimeric VLP containing Pfs25 or the Pfs230-derived fragments Pfs230c or Pfs230D1M were purified. Up to 100 mg chimeric VLP were isolated from 100 g dry cell weight with a maximum protein purity of 90% on the protein level. Expression of the Pfs230D1M construct was more efficient than Pfs230c and enabled VLP with higher purity. VLP showed reactivity with transmission-blocking antibodies and supported the surface display of the malaria antigens on the native VLP. CONCLUSION:The incorporation of leading Plasmodium falciparum transmission-blocking antigens into the dS-based VLP scaffold is a promising novel strategy for their display on nano-scaled particles. Competitive processes for efficient production and purification were established in this study. |
url |
https://doi.org/10.1371/journal.pone.0221394 |
work_keys_str_mv |
AT davidwetzel displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT joannechan displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT manfredsuckow displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT andreasbarbian displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT michaelweniger displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT volkerjenzelewski displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT lindareiling displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT jacksrichards displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT davidaanderson displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT bettykouskousis displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT catherinepalmer displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT erichanssen displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT gerhardschembecker displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT julianemerz displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT jamesgbeeson displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha AT michaelpiontek displayofmalariatransmissionblockingantigensonchimericduckhepatitisbvirusderivedviruslikeparticlesproducedinhansenulapolymorpha |
_version_ |
1714821976507285504 |